Daniel Camardo A.'s Insider Trades & SAST Disclosures
Daniel Camardo A.'s most recent trade in Athersys Inc was a trade of 19,993 Common Stock done at an average price of $0.4 . Disclosure was reported to the exchange on Oct. 4, 2023.
Add Superstar Alert
Note
This is a custom search result for pattern Daniel Camardo A..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
Athersys Inc
|
Daniel Camardo A. | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.44 per share. | 04 Oct 2023 | 19,993 | 285,341 (0%) | 0% | 0.4 | 8,797 | Common Stock |
|
Athersys Inc
|
Daniel A. Camardo | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.91 per share. | 05 Jul 2023 | 19,993 | 305,334 (0%) | 0% | 0.9 | 18,274 | Common Stock |
|
Athersys Inc
|
Daniel A. Camardo | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.00 per share. | 04 Apr 2023 | 19,993 | 325,327 (0%) | 0% | 1 | 19,993 | Common Stock |
|
Athersys Inc
|
Daniel A. Camardo | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.85 per share. | 04 Jan 2023 | 23,484 | 345,320 (0%) | 0% | 0.8 | 19,961 | Common Stock |
|
Athersys Inc
|
Daniel A. Camardo | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.55 per share. | 22 Nov 2022 | 100,000 | 368,804 (0%) | 0% | 0.5 | 54,960 | Common Stock |
|
Athersys Inc
|
Daniel A. Camardo | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2022 | 263,492 | 268,804 (0%) | 0% | 0 | Common Stock | |
|
Athersys Inc
|
Daniel A. Camardo | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.77 per share. | 17 Mar 2022 | 132,800 | 132,800 (0%) | 0% | 0.8 | 102,256 | Common Stock |
|
Athersys Inc
|
Daniel A. Camardo | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 4,000,000 | 4,000,000 | - | - | Stock Option (right to purchase) | |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.52 per share. | 05 Apr 2021 | 15,467 | 50,672 (0%) | 0% | 25.5 | 394,718 | Ordinary shares |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2021 | 15,467 | 4,333 | - | - | Employee stock option (right to buy) | |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2021 | 2,305 | 0 | - | - | Employee stock option (right to buy) | |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.19 per share. | 05 Apr 2021 | 2,305 | 35,205 (0%) | 0% | 17.2 | 39,623 | Ordinary shares |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2021 | 509 | 3,441 | - | - | Employee stock option (right to buy) | |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.23 per share. | 05 Apr 2021 | 509 | 51,181 (0%) | 0% | 15.2 | 7,752 | Ordinary shares |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Sale of securities on an exchange or to another person at price $ 84.97 per share. | 30 Mar 2021 | 4,594 | 39,403 (0%) | 0% | 85.0 | 390,352 | Ordinary Shares |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Sale of securities on an exchange or to another person at price $ 86.87 per share. | 30 Mar 2021 | 3,517 | 32,900 (0%) | 0% | 86.9 | 305,522 | Ordinary Shares |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Sale of securities on an exchange or to another person at price $ 85.88 per share. | 30 Mar 2021 | 2,986 | 36,417 (0%) | 0% | 85.9 | 256,438 | Ordinary Shares |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Sale of securities on an exchange or to another person at price $ 83.58 per share. | 30 Mar 2021 | 1,803 | 43,997 (0%) | 0% | 83.6 | 150,695 | Ordinary Shares |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2021 | 1,300 | 46,376 (0%) | 0% | - | Ordinary Shares | |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2021 | 1,300 | 0 | - | - | Restricted Stock Units | |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.87 per share. | 21 Feb 2021 | 576 | 45,800 (0%) | 0% | 88.9 | 51,189 | Ordinary Shares |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2021 | 3,220 | 46,503 (0%) | 0% | 0 | Ordinary Shares | |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2021 | 3,220 | 0 | - | - | Performance Restricted Stock Units (PSUs) | |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 77.43 per share. | 21 Jan 2021 | 1,427 | 45,076 (0%) | 0% | 77.4 | 110,493 | Ordinary Shares |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 20,957 | 20,957 | - | - | Restricted Stock Units (RSU) | |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 20,614 | 52,513 (0%) | 0% | - | Ordinary Shares | |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 10,626 | 10,626 | - | - | Restricted Stock Units (RSU) | |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 73.28 per share. | 04 Jan 2021 | 9,230 | 43,283 (0%) | 0% | 73.3 | 676,374 | Ordinary Shares |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 5,634 | 0 | - | - | Restricted Stock Units (RSU) | |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 4,354 | 8,708 | - | - | Restricted Stock Units (RSU) | |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Sale of securities on an exchange or to another person at price $ 76.76 per share. | 06 Nov 2020 | 3,500 | 30,829 (0%) | 0% | 76.8 | 268,663 | Ordinary Shares |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2020 | 10,000 | 0 | - | - | Restricted Stock Units | |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 10,000 | 38,789 (0%) | 0% | 0 | Ordinary Shares | |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.42 per share. | 01 Oct 2020 | 4,460 | 34,329 (0%) | 0% | 80.4 | 358,673 | Ordinary Shares |
|
Horizon Therapeutics Plc
|
Daniel A. Camardo | EVP and President, U.S. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2020 | 17,102 | 17,102 | - | - | Restricted Stock Units (RSU) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges